Future of Abaxis | Quantumrun

Future of Abaxis

At the Abaxis company, the aim is to make available blood analyzers with the point of care feature to the veterinarian and the medical market. Abaxis offers all the leading edge technologies, services, and tools. This ultimately supports the finest enabling physicians, veterinarians, and medical practices to act in response to the health necessities of their patrons through the point of care at the same time as operating on profitable and economic practices. Abaxis has its headquarters located in North California, USA, and carries out operations all over the world.

Home Country: 
United States
Industry: 
Portable blood analysis systems
Industry vulnerability to disruption: 

<p>Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.<br />
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.<br />
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.<br />
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.<br />
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.<br />
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.<br />
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.</p>

Total patents held: 
42
Ranking List: 
735
Ranking List: 
2017 Quantumrun Global 1000
480
Ranking List: 
2017 Quantumrun US 500
91
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
North America
Revenue from country 
0.80
Prod/Serv name revenue: 
Prod/Serv name: 
Veterinary market
Prod/Serv revenue: 
177667000
Prod/Serv name: 
Medical market
Prod/Serv revenue: 
37845000
Prod/Serv name: 
Other
Prod/Serv revenue: 
3389000
Founded: 
1989
Company Name: 
Abaxis
Sector: 
Revenue: 
227220000
3y average revenue: 
216238000
Operating expenses: 
81358000
3y average expenses: 
77640667
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
584
Number of domestic locations: 
1
Funds in reserve: 
88323000
Investment into R&D: 
19795000
create term: 
#735 | 2017 Quantumrun Global 1000
#480 | 2017 Quantumrun US 500
#91 | 2017 Quantumrun Silicon Valley 100

At the Abaxis company, the aim is to make available blood analyzers with the point of care feature to the veterinarian and the medical market. Abaxis offers all the leading edge technologies, services, and tools. This ultimately supports the finest enabling physicians, veterinarians, and medical practices to act in response to the health necessities of their patrons through the point of care at the same time as operating on profitable and economic practices. Abaxis has its headquarters located in North California, USA, and carries out operations all over the world.

Home country:
United States
Sector:
Health Care
Industry:
Portable blood analysis systems
Website:
Founded:
1989
Global employee count:
584

Financial Health

Revenue
$227,220,000 USD
3y average revenue
$216,238,000 USD
Operating expenses
$81,358,000 USD
3y average expenses
$77,640,667 USD
Funds in reserve
$88,323,000 USD
#1 Market country
North America
% of revenue from country #1
0.8%

Asset Performance

#1 Product/Service/Dept. name
Veterinary market
#1 Product/Service revenue
$177,667,000 USD
#2 Product/Service/Dept. name
Medical market
#2 Product/Service revenue
$37,845,000 USD
#3 Product/Service/Dept. name
Other
#3 Product/Service revenue
$3,389,000 USD

Innovation assets and Pipeline

Investment into R&D
$19,795,000 USD
Total patents held
42
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.